Epitome: How Much Real Runway Does the Cash Balance Still Provide?

The main article already framed Epitome's core shift, from a regulatory bottleneck to a commercial one. This follow-up isolates only the cash question, because that is where the widest gap sits between the first impression and the full economic picture.

At first glance, $13.648 million of cash at year-end 2025 looks like a reasonable cushion for a life-sciences company entering its first real commercialization year. But that is only half the picture. At year-end 2024, the company also held a $5.510 million short-term deposit next to cash. Once those two lines are combined, immediately available liquidity fell from $22.079 million to $13.648 million over 2025, and then slipped again to about $11.532 million near the financial-statement approval date. In other words, the cash clock moved faster than the year-end cash line alone suggests.

That is also why the framing matters. The question here is not the normalized cash-generation power of a mature business, because Epitome is not there yet. The question is how much financing flexibility remains before commercialization has to start offsetting the burn. For that reason, the right primary frame is all-in cash flexibility, meaning cash left after the period's real uses, not just after one operating-cash-flow line.

Three points stand out immediately:

• The cash line is somewhat flattering. Part of the apparent stability came from a short-term deposit maturing into cash, not from a real improvement in burn.
• The narrow frame tells a cleaner story than the real one. Operating cash burn was $7.660 million, but lease cash and fixed-asset investment pushed the total cash use higher.
• Europe has not solved funding yet. The March 2026 update includes an immediate order of about $110 thousand and a 12-month framework order of about $5.3 million. That is meaningful commercial progress, but it is still not a cash substitute.

What is left once the deposit effect is stripped out

The first issue that matters is not just the drop in cash from $16.569 million to $13.648 million. The bigger point is that year-end 2025 cash was no longer supported by the short-term deposit that existed a year earlier. Put differently, year-end 2025 looks better on the cash line than it does on a full liquidity view.

The implication is straightforward. Anyone who looked only at the cash line saw a decline of about $2.9 million in 2025. Anyone who also included the short-term deposit saw a drop of about $8.4 million in immediately available liquidity. Then, between 31 December 2025 and 22 March 2026, another roughly $2.1 million disappeared. That is not a collapse, but it is also not a cash balance sitting still.

This point matters because management and the board state that the company has sufficient resources to continue as a going concern and meet its obligations for the foreseeable future. The analysis here does not contradict that statement. It simply narrows the margin for error inside it. If commercial ramp-up is slow, the cash line can shorten materially faster than the headline message implies.

The all-in bridge, where the money actually went

The right way to read 2025 is through a full cash bridge. Cash used in operating activities was $7.660 million. On top of that came $673 thousand of lease-principal repayments and $1.831 million of investment in property, plant and equipment. Those are real cash uses, so they have to sit inside the frame.

There are two important takeaways in that bridge. First, the real 2025 burn on an all-in basis was not $7.660 million but about $10.164 million before deposit interest and FX. Second, part of the cash drain already belongs to commercialization itself. Inventory rose from $16 thousand to $470 thousand because the company started commercial production and built raw-material and work-in-process inventory. In other words, early sales do not enter the model without an upfront cost in working capital and operations.

That also explains why 2025 was not just another R&D year. Cost of sales already reached $867 thousand, while net property, plant and equipment rose to $13.462 million, partly because of additional production machinery. Any view that says commercialization will automatically make the burn disappear is skipping over the fact that commercial scale-up itself is a cash-demanding phase.

2026 already arrives with a visible spending floor

The next important layer in the filing is the forward spending plan. For the coming year, the company estimates about $1.85 million of R&D investment in the weight-loss capsule activity, mainly for expanding production capacity and broadening regulatory reach, plus another roughly $1.6 million for the oral drug-delivery platform. Together that is about $3.45 million. This is not the full 2026 cost base. It is only the clearly disclosed R&D layer that management itself is flagging.

The liquidity-risk note adds another layer. As of 31 December 2025, the company had $1.192 million of contractual financial liabilities due within one year, including $733 thousand of lease obligations, $313 thousand to suppliers and $146 thousand in other payables. Beyond that, total contractual lease cash commitments stood at $7.336 million, of which $5.890 million sit beyond two years.

The point of that chart is not that 2026 will amount to only $4.642 million. It is the opposite. This is merely the floor that is already fairly visible in the filings. On top of it sit G&A, selling costs, inventory, production upkeep and any additional capital spending if commercialization progresses. So any liquidity story built only on the cash balance and the new European order is looking at the easy side of the equation.

The sharpest line appears in the liquidity-risk note itself. The company says explicitly that because it still does not have meaningful cash flow from operating activities, its funding sources rely on issuing equity instruments to shareholders. That sentence matters because it translates the cash question directly into a dilution question. If commercialization does not begin to carry part of the model, the default fallback is not the banking system. It is the equity market.

When commercialization has to start carrying the model

This is where the gap between the two reading frames becomes useful. If one uses only the 2025 operating cash burn of $7.660 million, then the roughly $11.532 million cash balance near report approval implies about 18.1 months of theoretical runway. That is the more comfortable story.

Once the frame moves to all-in cash flexibility, however, and adds the $673 thousand of lease-principal repayments plus the $1.831 million of reported fixed-asset investment, the annual denominator rises to about $10.164 million. On that basis, the same near-approval cash balance translates into only about 13.6 months of theoretical runway.

This is not management guidance and not a binding timetable. It is simply the arithmetic implied by late 2025 and early 2026. But that arithmetic says something important, Epitome does not need to become profitable immediately, yet it does need to show in the coming reports that commercialization is starting to bend the burn curve.

The European event illustrates the distinction well. In March 2026, the company received a binding framework order of about $5.3 million for the coming 12 months, alongside an immediate order of about $110 thousand. That is an excellent commercial signal, but it is still not immediate cash. First, because the immediate order is small relative to the cash question. Second, because the balance is spread over 12 months. Third, because the company itself says realization of the framework order remains forward-looking information. And fourth, because even full revenue realization is not the same as free cash in a company that is still climbing a manufacturing and commercialization ramp.

Israel teaches the same lesson. A first shipment went out on 18 December 2025 and produced the company's first recognized revenue, about $213 thousand. A second shipment followed in March 2026. So commercialization has genuinely started. But it is still too small to carry the model, and certainly too small to remove the question of the next capital test.

Bottom line

The bottom line of this continuation is simpler than it first appears. Epitome has cash. There is no immediate funding crisis here. But there is also not a huge surplus of time. Anyone looking only at the year-end cash balance gets an overly calm picture, because that view ignores the deposit that disappeared, the lease cash, the CAPEX and the fact that commercialization itself is beginning to consume capital.

The central conclusion is that the distance between "sufficient resources for the foreseeable future" and "another funding test is approaching" is mostly a matter of execution. If Germany, Israel and then the broader commercial channels start producing recurring orders, shipments and cash over the next 2 to 4 quarters, Epitome can push that question out and enter 2027 from a stronger place. If conversion is slow, the liquidity note already hints at where the solution would come from, equity rather than internally generated cash.